-
Tytuł:
-
Efficacy of recombinant Marek's disease virus vectored vaccines with computationally optimized broadly reactive antigen (COBRA) hemagglutinin insert against genetically diverse H5 high pathogenicity avian influenza viruses.
-
Autorzy:
-
Bertran K; Exotic and Emerging Avian Viral Diseases Research Unit, Southeast Poultry Research Laboratory, United States National Poultry Research Center, Agricultural Research Service, US Department of Agriculture, 934 College Station Rd, Athens, GA 30605, USA. Electronic address: .
Kassa A; Boehringer Ingelheim Animal Health USA Inc, 1730 Olympic Drive, Athens, GA 30601, USA. Electronic address: .
Criado MF; Exotic and Emerging Avian Viral Diseases Research Unit, Southeast Poultry Research Laboratory, United States National Poultry Research Center, Agricultural Research Service, US Department of Agriculture, 934 College Station Rd, Athens, GA 30605, USA. Electronic address: .
Nuñez IA; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA. Electronic address: .
Lee DH; Department of Pathobiology & Veterinary Science, University of Connecticut, Storrs, CT 06269, USA. Electronic address: .
Killmaster L; Exotic and Emerging Avian Viral Diseases Research Unit, Southeast Poultry Research Laboratory, United States National Poultry Research Center, Agricultural Research Service, US Department of Agriculture, 934 College Station Rd, Athens, GA 30605, USA. Electronic address: .
Sá E Silva M; Boehringer Ingelheim Animal Health USA Inc, 1730 Olympic Drive, Athens, GA 30601, USA. Electronic address: mariana.sa_e_.
Ross TM; Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA; Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA. Electronic address: .
Mebatsion T; Boehringer Ingelheim Animal Health USA Inc, 1730 Olympic Drive, Athens, GA 30601, USA. Electronic address: .
Pritchard N; Boehringer Ingelheim Animal Health USA Inc, 1112 Airport Parkway, Gainesville, GA 30503, USA. Electronic address: .
Swayne DE; Exotic and Emerging Avian Viral Diseases Research Unit, Southeast Poultry Research Laboratory, United States National Poultry Research Center, Agricultural Research Service, US Department of Agriculture, 934 College Station Rd, Athens, GA 30605, USA. Electronic address: .
-
Źródło:
-
Vaccine [Vaccine] 2021 Apr 01; Vol. 39 (14), pp. 1933-1942. Date of Electronic Publication: 2021 Mar 11.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Amsterdam, The Netherlands : Elsevier Science
Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
-
MeSH Terms:
-
Influenza A Virus, H5N1 Subtype*/genetics
Influenza Vaccines*
Influenza in Birds*/prevention & control
Marek Disease*/prevention & control
Animals ; Antibodies, Viral ; Chickens ; Hemagglutinin Glycoproteins, Influenza Virus/genetics ; Hemagglutinins ; Vaccines, Synthetic/genetics ; Virulence
-
Contributed Indexing:
-
Keywords: Avian influenza; COBRA; H5; HPAIV; HVT recombinant vector vaccine
-
Substance Nomenclature:
-
0 (Antibodies, Viral)
0 (Hemagglutinin Glycoproteins, Influenza Virus)
0 (Hemagglutinins)
0 (Influenza Vaccines)
0 (Vaccines, Synthetic)
-
Entry Date(s):
-
Date Created: 20210315 Date Completed: 20210524 Latest Revision: 20210524
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.vaccine.2021.02.075
-
PMID:
-
33715903
-
The genetic and antigenic drift associated with the high pathogenicity avian influenza (HPAI) viruses of Goose/Guangdong (Gs/GD) lineage and the emergence of vaccine-resistant field viruses underscores the need for a broadly protective H5 influenza A vaccine. Here, we tested experimental vector herpesvirus of turkey (vHVT)-H5 vaccines containing either wild-type clade 2.3.4.4A-derived H5 inserts or computationally optimized broadly reactive antigen (COBRA) inserts with challenge by homologous and genetically divergent H5 HPAI Gs/GD lineage viruses in chickens. Direct assessment of protection was confirmed for all the tested constructs, which provided clinical protection against the homologous and heterologous H5 HPAI Gs/GD challenge viruses and significantly decreased oropharyngeal shedding titers compared to the sham vaccine. The cross reactivity was assessed by hemagglutinin inhibition (HI) and focus reduction assay against a panel of phylogenetically and antigenically diverse H5 strains. The COBRA-derived H5 inserts elicited antibody responses against antigenically diverse strains, while the wild-type-derived H5 vaccines elicited protection mostly against close antigenically related clades 2.3.4.4A and 2.3.4.4D viruses. In conclusion, the HVT vector, a widely used replicating vaccine platform in poultry, with H5 insert provides clinical protection and significant reduction of viral shedding against homologous and heterologous challenge. In addition, the COBRA-derived inserts have the potential to be used against antigenically distinct co-circulating viruses and future drift variants.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AK, MSS, TM, and NP are employees of Boehringer Ingelheim Animal Health. DES declares receipt of a research grant from Boehringer Ingelheim Animal Health.
(Published by Elsevier Ltd.)
